573 related articles for article (PubMed ID: 33930416)
1. Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: A comprehensive review.
Liu WT; Chen EZ; Yang L; Peng C; Wang Q; Xu Z; Chen DQ
Microb Pathog; 2021 Jul; 156():104915. PubMed ID: 33930416
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
Saravolatz LD; Pawlak J
J Antimicrob Chemother; 2022 Dec; 78(1):238-241. PubMed ID: 36374572
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of antibiotic susceptibilities and VISA-VRSA rates among MRSA strains isolated from hospitalized patients in intensive care units of hospitals in seven provinces of Turkey].
Cesur S; Irmak H; Simşek H; Cöplü N; Kılıç H; Arslan U; Bayramoğlu G; Baysan BO; Gülay Z; Hoşoğlu S; Berktaş M; Gencer S; Demiröz AP; Esen B; Karabiber N; Aydın F; Yalçın AN
Mikrobiyol Bul; 2012 Jul; 46(3):352-8. PubMed ID: 22951647
[TBL] [Abstract][Full Text] [Related]
4. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.
Holubar M; Meng L; Deresinski S
Infect Dis Clin North Am; 2016 Jun; 30(2):491-507. PubMed ID: 27208769
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
6. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
[TBL] [Abstract][Full Text] [Related]
7. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
Saravolatz LD; Pawlak JM; Wegner C
J Antimicrob Chemother; 2020 Sep; 75(9):2605-2608. PubMed ID: 32542310
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ceftaroline in combination with other antimicrobials active against Staphylococcus spp.
Gil Romero Y; Gómez-Garcés JL
Enferm Infecc Microbiol Clin (Engl Ed); 2020 Jan; 38(1):25-27. PubMed ID: 31072712
[TBL] [Abstract][Full Text] [Related]
9. The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.
Shariati A; Dadashi M; Chegini Z; van Belkum A; Mirzaii M; Khoramrooz SS; Darban-Sarokhalil D
Antimicrob Resist Infect Control; 2020 Apr; 9(1):56. PubMed ID: 32321574
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
12. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.
Holubar M; Meng L; Alegria W; Deresinski S
Infect Dis Clin North Am; 2020 Dec; 34(4):849-861. PubMed ID: 33011050
[TBL] [Abstract][Full Text] [Related]
13.
Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
[TBL] [Abstract][Full Text] [Related]
15. Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.
Fang H; Fröding I; Gian B; Hæggman S; Tollström UB; Ullberg M; Nord CE
J Glob Antimicrob Resist; 2016 Jun; 5():31-5. PubMed ID: 27436463
[TBL] [Abstract][Full Text] [Related]
16. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
Ghahremani M; Jazani NH; Sharifi Y
J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
[TBL] [Abstract][Full Text] [Related]
19. Treatment of infections due to resistant Staphylococcus aureus.
Anstead GM; Cadena J; Javeri H
Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702
[TBL] [Abstract][Full Text] [Related]
20. [Antibiotics for treatment of infections by methicillin-resistant Staphylococcus aureus (MRSA)].
Stahlmann R
Pneumologie; 2014 Oct; 68(10):676-84. PubMed ID: 25290922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
